FIELD: medicine.
SUBSTANCE: invention concerns medicine, namely to vaccinal prevention, and can be used for specific prevention of hepatitis B in children with oncologic diseases in past history. That is ensured by revaccination in the children underwent the primary vaccination, 3-6 months after consolidating chemo- or radiation therapy. Herewith, at first hepatitis B antibody titres are determined. The titre 10 mMe/ml and less enables to administer the vaccine in a dose 0.5 ml. The titres are determined again 30 days later. The titre exceeding 10 mMe/ml, the vaccination is not applied, while the titre 10 mMe/ml ensures to introduce the second additional dose - 0.5 ml of the vaccine. Then 5 months later the titre more than 10 mMe/ml enables to consider the vaccination finished, and the third additional dose 0.5 ml of the vaccine is required with the titre less than 10 mMe/ml.
EFFECT: invention provides formation of steady protective hepatitis B antibody titres that allows to preventing viral infection in given category of patients.
5 ex, 1 tbl
